Skip to main content
. 2015 Dec 15;8(12):22117–22128.

Figure 2.

Figure 2

Pooled mean difference in the changes of body weight (A) and serum sodium (B) in the studies considering tolvaptan compared to placebo therapy in HF patients. There were significant decreases in the change of body weight in each dose of tolvaptan (15 mg: MD=-1.09, 95% CI=-1.50 to -0.68, P<0.001; 30 mg: MD=-0.82, 95% CI=-0.89 to -0.74, P<0.001; 45 mg: MD=-1.29, 95% CI=-1.52 to -1.05, P<0.001). The overall effect showed a statistical significance (MD=-0.87, 95% CI=-0.94 to -0.80, P<0.001), but there was no dose dependence. Significant increase was found between tolvaptan and placebo groups at day 1 (MD=2.93, 95% CI=2.70 to 3.16, P<0.001) and at day 7 or discharge (MD=3.10, 95% CI=2.78 to 3.42, P<0.001). The overall effect showed a statistical significance (MD=2.99, 95% CI=2.80 to 3.18, P<0.001).